COMP <GO>
MOLN vs TARA // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Molecular Partners AG (NASDAQ) VS. Protara Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: MOLN 1
— TARA 1
■ METRIC PARITY
LAST: $3.48 (-2.79%) • MKT CAP: $134.3M
options-implied-move
—
LAST: $2.41 (-2.82%) • MKT CAP: $146.6M
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MOLN VS. TARA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MOLN | TARA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -34.70% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 2/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.5 | 38.3 | +3.20 | MOLN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $134.3M | $146.6M | -$12.3M | TARA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MOLN REV | TARA REV | MOLN GROSS % | TARA GROSS % | MOLN FCF | TARA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $180.7M | — | — | — | -$56.5M |
| FY 2024 | — | $137.6M | — | — | — | -$35.9M |
| FY 2023 | — | $122.1M | — | — | — | -$37.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MOLN // BETA —
TARA // BETA —